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ABSTRACT
Background: There have been few studies to evaluate the prognostic implications of 
guideline-directed therapy according to the temporal course of heart failure. This study 
assessed the relationship between adherence to guideline-directed therapy at discharge 
and 60-day clinical outcomes in de novo acute heart failure (AHF) and acute decompensated 
chronic heart failure (ADCHF) separately.
Methods: Among 5,625 AHF patients who were recruited from a multicenter cohort registry 
of Korean Acute Heart Failure, 2,769 patients with reduced ejection fraction were analyzed. 
Guideline-directed therapies were defined as the use of angiotensin-converting enzyme 
inhibitor (ACEI) or angiotensin receptor II blocker (ARB), β-blocker, and mineralocorticoid 
receptor antagonist.
Results: In de novo AHF, ACEI or ARB reduced re-hospitalization (hazard ratio [HR], 
0.57; 95% confidence interval [CI], 0.34–0.95), mortality (HR, 0.41; 95% CI, 0.24–0.69) 
and composite endpoint (HR, 0.52; 95% CI, 0.36–0.77) rates. Beta-blockers reduced re-
hospitalization (HR, 0.62; 95% CI, 0.41–0.95) and composite endpoint (HR, 0.65; 95% CI, 
0.47–0.90) rates. In ADCHF, adherence to ACEI or ARB was associated with only mortality 
and β-blockers with composite endpoint.
Conclusion: The prognostic implications of adherence to guideline-directed therapy at 
discharge were more pronounced in de novo heart failure. We recommend that guideline-
directed therapy be started as early as possible in the course of heart failure with reduced 
ejection fraction.
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INTRODUCTION
The American College of Cardiology (ACC)/American Heart Association (AHA) and the 
European Society of Cardiology (ESC) have developed evidence-based guidelines for the 
treatment of heart failure (HF) to assist clinicians in clinical decision-making by describing 
acceptable approaches to the diagnosis, management, and prevention of specific diseases 
or conditions.1,2 In chronic HF with reduced ejection fraction (HFrEF), evidence-based 
benefit on outcome is documented for angiotensin-converting enzyme inhibitors (ACEI), 
angiotensin-receptor II blockers (ARB), β-blockers, mineralocorticoid receptor antagonists 
(MRA), angiotensin receptor neprilysin inhibitors (ARNI), and ivabradine. However, acute 
heart failure (AHF) is characterized by rapid worsening of symptoms and signs of HF. 
Although survival rates have improved, mortality is still high, typically greater than 4%. 
However, most morbidity and mortality of hospitalized AHF occurs early after index hospital 
discharge.3,4 Hospitalized HF patients have 30-day readmission rates from 20% to 27%, with 
mortality rate reaching up to 12.2% at 30-days.5,6 Once the patient is stabilized, the priority 
should transition to initiation of chronic medical therapy. Modalities initiated in the hospital 
engender increased outpatient adherence and improved outcomes. Therefore, comprehensive 
strategies must focus on factors during hospitalization and during the early recovery 
period soon after discharge to target stressors that contribute to patient vulnerability. The 
guideline-directed therapy in HF inpatient is associated with post-discharge mortality or 
re-hospitalization.7-9 AHF has two forms according to the time course of heart failure: newly 
arisen (“de novo”) AHF and acutely decompensated chronic heart failure (ADCHF).1,2 Acute 
and chronic HF differ both in their temporal course and treatment.3,10 However, there are 
limited data regarding the prognostic implications of guideline-directed therapy according to 
the temporal course of HF. We assessed the relationship between guideline-directed therapy 
at discharge and 60-day relevant patient clinical outcomes, including all-cause mortality, 
re-hospitalization because of aggravated HF, and composite endpoint of mortality or HF 
hospitalization in de novo AHF and ADCHF separately.
METHODS
Study population
We used the registry of Korean Acute Heart Failure (KorAHF), which is a multicenter 
prospective cohort study. Between March 2011 and February 2014, the registry prospectively 
enrolled 5,625 consecutive patients admitted for treatment of AHF from 10 tertiary university 
hospitals. Patients were followed-up until 2018. The registry included patients with signs or 
symptoms of HF who met at least one of the following inclusion criteria: 1) lung congestion 
or 2) objective findings of left ventricular systolic dysfunction (LVSD) or structural heart 
disease. Detailed information on the study design and results of the KorAHF registry have 
been described previously.11
Adherence to guideline-directed therapy
Guideline-directed therapy was defined by ACC/AHA and ECS guidelines.1,2 Numerators were 
defined as HF patients who were prescribed each medication and denominator as HF patients 
with LVSD and without contraindication for medication. The adherence to guideline-directed 
therapy was assessed by the ratio of the numerator to the dominator.12,13 Of these guideline-
directed therapies, we excluded ARNI and ivabradine because this therapy was not available 
in Korea during the study period.
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The adherence to guideline-directed therapy was defined as follows: 1) β-blocker therapy 
for LVSD: percentage of patients who were prescribed β-blocker therapy with bisoprolol, 
carvedilol, sustained-release metoprolol succinate, or nebivolol at hospital discharge. 
Because the 2016 ESC guidelines for HF recommend β-blockers, including nebivolol, for the 
treatment of HFrEF, patients prescribed nebivolol were defined as numerators.14 Patients 
not eligible for β-blocker therapy were those with systolic blood pressure < 90 mmHg or 
resting heart rate < 60 bpm at discharge.2 An equivalent dose of carvedilol was calculated 
for bisoprolol- and nebivolol-treated subjects (dose × 5), and for metoprolol-treated subjects 
(dose/4), again taking into account several possible confounders15; 2) ACEI or ARB therapy 
for LVSD: percentage of patients who were prescribed ACEI or ARB therapy at hospital 
discharge. Patients not eligible for ACEI or ARB therapy were those with systolic blood 
pressure < 90 mmHg or serum creatinine > 2.5 mg/dL or serum K ≥ 5.0 mmol/L at discharge.2 
Equivalent doses of ramipril were calculated for ACEI, and equivalent doses of candesartan 
were calculated for ARB.16
An additional performance measure for MRA was developed, excluding patients with 
documented MRA contraindications or intolerance (serum K ≥ 5.0 mmol/L or creatinine  
> 2.5 mg/dL at discharge).2
Clinical outcomes
The follow-up data were collected from the patients by the attending physician and stored in 
a web-based case report form. The outcome data of subjects who had not been followed-up 
were ascertained by telephone interview. In addition, the outcome data of patients lost to 
follow-up were collected from the National Death Records. All clinical events, such as death 
and re-hospitalization were monitored and verified by a Clinical Event Committee comprising 
independent experts in HF who did not participate in patient enrolment for the study.11 The 
outcomes were 60-day all-cause mortality, re-hospitalization because of aggravated HF, and 
composite endpoint of mortality or HF hospitalization.
Statistical analysis
Statistical analyses were conducted by the Center of Biomedical Data Science, Yonsei University, 
Wonju College of Medicine. Continuous variables are expressed as mean ± SD and categorical 
variables as percentages. For continuous variables, the independent t-test was used, and for 
dichotomous variables, the χ2 test was adopted, as appropriate. The Kaplan-Meier method 
was used to report survival curves and estimate the mean survival, and the 95% confidence 
interval (CI) and the log rank test were applied. Cox proportional hazards regression models 
were used to estimate hazard ratios (HRs) and their 95% CIs. Models were adjusted for gender; 
age; history of hypertension, diabetes mellitus, ischemic heart disease, and chronic obstructive 
pulmonary disease; New York Heart Association functional class; systolic blood pressure; heart 
rate; creatinine; presence of atrial fibrillation at admission; and LVEF. Model discrimination 
was assessed using Harrell's C-statistic. In all cases, a P value < 0.05 was considered statistically 
significant. Statistical analyses were performed using SAS 9.4 (SAS Inc., Cary, NC, USA) and R 
software version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).
Ethics statement
The study protocol was approved by the ethics committee at each hospital and the Wonju 
Christian Hospital, Wonju College of Medicine, Yonsei University (Wonju, Korea; Approval 
No. CR311003), and written informed consent was obtained from each patient or their 
relative or legal representative.
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RESULTS
Baseline characteristics of the study population and clinical outcomes
Of 5,625 patients, we selected patients with LVSD, which was defined as LVEF < 40% using 
echocardiography. After excluding 272 patients without quantitative LVEF data and 83 heart 
transplantation candidates, 2,769 patients were analyzed (Fig. 1). Patients were classified 
by the attending physician according to the contemporary guidelines on AHF, based on the 
clinical presentation at admission. ADCHF was defined as worsening of HF in patients with 
a previous diagnosis or hospitalization for HF. De novo AHF, defined as AHF in patients with 
no prior history of HF14 included 1,417 patients. There were 1,352 patients with ADCHF. 
Demographic characteristics were significantly different between the 2 groups. Patients 
with ADCHF were older and had lower body weight, blood pressure, and heart rate than 
did patients with de novo AHF. ADCHF patients had higher rates of comorbid disease. 
Electrocardiographically, atrial fibrillation and left bundle branch block were more prevalent 
in ADCHF. At admission, sodium and hemoglobin levels were lower and creatinine and 
N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were higher in patients with 
ADCHF. On echocardiography, patients with ADCHF had a more deteriorated heart function 
(Table 1). In patients with ADCHF, 60-day rehospitalization (14.3% vs. 6.8%; P < 0.001), 
mortality (8.2% vs. 5.9%; P = 0.02), and composite endpoint (20.6% vs. 11.8%; P < 0.001) 
rates were higher compared with those in patients with de novo HF (Supplementary Table 1).
Discharge medication and guideline adherence
Compliance rates for performance measures ranged from high for ACEI or ARB (84.5%) to 
low for β-blocker (64.5%) and MRA therapy (58.1%) in patients with de novo AHF. Compliance 
with ACEI or ARB (75.2%), β-blocker (52.9%), and MRA (56.1%) decreased in patients with 
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Incomplete echo data: 272
EF ≥ 40: 2,351
In-hospital death: 150
Heart transplantation: 83
Korean acute heart failure registry (KorAHF) 
n = 5,625
Heart failure with LVEF < 40% 
n = 3,002
Survival discharge with LVEF < 40% 
n = 2,769
De novo heart failure 
n = 1,417
Acute decompensated heart failure 
n = 1,352
Fig. 1. Flow diagram of patients included. 
LVEF = left ventricular ejection fraction.
ADCHF (Supplementary Table 2). With regard to medication at discharge, the calculated 
equivalent doses for ACEI, ARB, β-blockers, and MRA were compared, and they did not differ 
between the 2 groups (Table 2).
5/12https://jkms.org https://doi.org/10.3346/jkms.2019.34.e133
Guideline-Directed Therapy in Heart Failure
Table 1. Baseline characteristics of the study population
Characteristics De novo AHF (n = 1,417) ADCHF (n = 1,352) P value
Demographic characteristic at admission
Gender, men 873 (61.6) 816 (60.4) 0.50
Age, yr 63.9 ± 15.6 69.0 ± 13.2 < 0.001
Height, cm 162.6 ± 9.2 161.2 ± 9.3 < 0.001
Weight, cm 62.5 ± 14.1 59.9 ± 12.6 < 0.001
Body mass index, kg/m2 23.5 ± 4.0 22.9 ± 3.7 < 0.001
Systolic blood pressure, mmHg 133.9 ± 30.1 125.7 ± 28.2 < 0.001
Diastolic blood pressure, mmHg 83.9 ± 20.0 76.8 ± 17.1 < 0.001
Heart rate, beat/min 99.3 ± 25.1 92.5 ± 24.5 < 0.001
NYHA functional class 0.13
Class II 206 (14.5) 182 (13.5)
Class III 503 (35.5) 530 (39.2)
Class IV 708 (50.0) 640 (47.3)
Comorbidity
Hypertension 725 (51.2) 817 (60.4) < 0.001
Diabetes mellitus 460 (32.5) 566 (41.9) < 0.001
Ischemic heart disease 227 (16.0) 604 (44.7) < 0.001
Chronic kidney disease 137 (9.7) 271 (20.0) < 0.001
Chronic obstructive pulmonary disease 123 (9.0) 165 (12.2) 0.01
Medication at admission
ACEI 96 (26.0) 273 (74.0) < 0.001
ARB 243 (17.0) 494 (36.5) < 0.001
β-blocker 188 (13.3) 561 (41.5) < 0.001
MRA 110 (7.8) 437 (32.3) < 0.001
Etiology of heart failure < 0.001
Ischemic heart disease 538 (38.0) 598 (44.2)
Valvular heart disease 63 (4.4) 137 (10.1)
Cardiomyopathy 447 (31.5) 402 (29.7)
ECG characteristics at admission
Atrial fibrillation at admission 362 (25.5) 454 (33.6) < 0.001
Left bundle branch block 90 (6.4) 128 (9.5) < 0.001
Right bundle branch block 64 (4.5) 93 (6.9) 0.01
Laboratory characteristics at admission
Na, mmol/L 138.2 ± 4.2 136.9 ± 4.8 < 0.001
K, mmol/L 4.3 ± 0.7 4.5 ± 0.7 < 0.001
Albumin, g/dL 3.7 ± 0.5 3.7 ± 0.5 0.91
Hemoglobin, g/dL 13.1 ± 2.4 12.4 ± 2.2 < 0.001
Creatinine, mg/dL 1.4 ± 1.6 1.6 ± 1.5 < 0.001
hs-CRP, mg/dL 2.1 ± 3.5 2.1 ± 4.1 0.96
NT-proBNP, pg/mL 9,308.9 ± 11,845.1 11,506.2 ± 11,171.0 < 0.001
BNP, pg/mL 1,597.9 ± 1,466.3 1,636.0 ± 1,381.7 0.67
CK-MB, ng/mL 9.4 ± 27.8 5.2 ± 12.0 < 0.001
Troponin I, mg/mL 3.2 ± 22.2 0.6 ± 2.8 < 0.001
Echocardiographic characteristics
LVEF, % 27.3 ± 7.9 26.2 ± 7.9 < 0.001
LVEDV, mL 166.5 ± 68.2 188.0 ± 76.5 < 0.001
LVESV, mL 119.6 ± 55.6 138.2 ± 64.1 < 0.001
LA dimension, mm 46.1 ± 8.0 49.9 ± 9.2 < 0.001
Values are presented as number (%) or mean ± standard deviation, unless otherwise indicated.
AHF = acute heart failure, ADCHF = acutely decompensated chronic heart failure, NYHA = New York Heart 
Association, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = 
mineralocorticoid receptor antagonists, ECG = electrocardiography, hs-CRP = high-sensitivity C-reactive protein, 
NT-proBNP = N-terminal-proBNP, BNP = B-type natriuretic peptide, CK-MB = creatinine kinase-MB, LVEF = left 
ventricular ejection fraction, LVEDV = left ventricular end diastolic volume, LVESV = left ventricular end systolic 
volume, LA = left atrium.
Adherence to guideline-directed therapy-outcome link in de novo AHF
The 60-day event free survival curves for each guideline-directed therapy are illustrated 
in Fig. 2. After adjustment for clinical risk factors, ACEI or ARB at discharge significantly 
reduced re-hospitalization (HR, 0.57; 95% CI, 0.34–0.95), mortality (HR, 0.41; 95% CI, 
0.24–0.69), and composite endpoint (HR, 0.52; 95% CI, 0.36–0.77) rates during the 6-month 
follow-up period. Beta-blockers had a protective effect against re-hospitalization (HR, 0.62; 
95% CI, 0.41–0.95) and composite endpoint (HR, 0.65; 95% CI, 0.47–0.90), but the effect on 
mortality was not significant (HR, 0.67; 95% CI, 0.42–1.06). After multivariate adjustment, 
MRA was not associated with any of the endpoints (Table 3).
Adherence to guideline-directed therapy-outcome link in ADCHF
Fig. 3 shows the Kaplan-Meier curves for each outcome according to each guideline-directed 
therapy for 60 days after discharge in ADCHF. After multivariable adjustment, the use of 
ACEI or ARB at discharge was significantly associated with mortality (HR, 0.58; 95% CI, 
0.38–0.89). β-blockers reduced the risk of 60-day composite endpoint (HR, 0.71; 95% CI, 
0.55–0.91), but their protective effect on re-hospitalization (HR, 0.75; 95% CI, 0.55–1.01) and 
mortality (HR, 0.67; 95% CI, 0.45–1.01) did not reach statistical significance. There was no 
association between MRA and any of the endpoints (Table 3).
DISCUSSION
In this analysis, baseline characteristics of patients admitted due to AHF were significantly 
different according to the temporal course of heart failure. The guideline-recommended 
therapy at discharge, including ACEI/ARB or β-blockers, was associated with improvements 
in 60-day prognosis in patients with de novo AHF, except that β-blockers did not improve 
the 60-day mortality. In patients with ADCHF, ACEI/ARB was associated with mortality and 
β-blockers with composite endpoint. MRA had no effect on the prognosis in both types of HF.
De novo HF is different from ADCHF
AHF has two forms: newly arisen (“de novo”) acute HF and ADCHF according to the temporal 
course. The differences in baseline characteristics and prognoses in de novo AHF and ADCHF 
are well-established.17 In the EuroHeart Failure Survey (EHFS) II, patients with a previous 
history of HF had worse long-term prognoses than those with de novo AHF, and concomitant 
diseases are more common in patients with ADCHF.3 In concordance with a previous study, our 
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Table 2. Medical therapy at discharge
Variables De novo AHF (n = 1,417) ADCHF (n = 1,352) P value
ACEI or ARB
ACEI at discharge
Ramipril equivalent dose, mg 2.9 ± 2.3 3.0 ± 2.3 0.65
Titration to target dose, No. (%) 32 (2.3) 22 (1.6) 0.23
ARB at discharge
Candesartan equivalent dose, mg 11.3 ± 8.3 10.5 ± 7.1 0.09
Titration to target dose, No. (%) 44 (3.1) 25 (1.8) 0.03
β-blocker at discharge
Carvedilol equivalent dose, mg 16.2 ± 15.9 16.0 ± 16.9 0.82
Titration to target dose, No. (%) 66 (4.7) 51 (3.8) 0.25
MRA at discharge
MRA dose, mg 23.8 ± 13.3 24.2 ± 14.5 0.56
AHF = acute heart failure, ADCHF = acutely decompensated chronic heart failure, ACEI = angiotensin-converting 
enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists.
study identified important differences in prognoses for different types of HF. Patients with a 
previous history of HF had worse long-term prognosis than those with de novo AHF. Importantly, 
concomitant diseases are more common in patients with ADCHF than those in patients with de 
novo AHF. Thus, ADCHF is associated with more severe symptoms, LV dysfunction, and worse 
prognosis than de novo HF, and these 2 conditions should be kept distinct.
Guideline-directed therapy in the time course of heart failure
It is well established that cardiac dysfunction is generally progressive even when there are no 
signs and symptoms of HF. The progression of heart failure is associated with left ventricular 
remodeling, which manifests as gradual increases in left ventricular end-diastolic and 
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Fig. 2. 60-day event free survival according to the adherence of performance measures at discharge in de novo HF (blue line: with adherence, red line: without 
adherence). 
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor II blocker, MRA = mineralocorticoid receptor antagonists, HF = heart failure.
end-systolic volumes, wall thinning, and a change in chamber geometry. Due to continuous 
maladaptive remodeling, myocardial dysfunction is usually a progressive condition, where 
even mild initial dysfunction may develop into severe HF over a time course of months to 
years.18 Neurohormonal activation including the sympathetic nervous system and renin 
angiotensin system in HF is known to be a major mediator of the remodeling process.19 
Therapeutic manipulation of these pathways with β-blockers, ACEIs, ARBs, and MRA has 
become the cornerstone of the management of HF. Consequently, early initiation of these 
neurohumoral pathway modulators may prevent or slow ventricular remodeling.20,21 In acute 
myocardial infarction, the mortality reduction effect of ACEIs early in the course of treatment 
is proved in a previous study. In a systematic overview of individual data from 96,712 acute 
myocardial infarction patients, 30-day mortality was 7.1% among patients allocated to early 
initiation of ACE Is and 7.6% among control subjects, corresponding to a 7% (SD, 2%) 
proportional reduction (95% CI, 2%–11%; P = 0.004).22 In the Carvedilol Post Infarction 
Survival Control in left ventricular dysfunction (CAPRICORN) study that enrolled patients 
with myocardial infarction occurring 3–21 days before randomization; all-cause mortality 
alone was lower in the carvedilol group than that in the placebo group (HR, 0.77; 95% CI, 
0.60–0.98; P = 0·03).23 At 6 months, left ventricular end systolic volume was 9.2 mL less in 
the carvedilol group than that in the placebo group (P = 0.023), and left ventricular ejection 
fraction was 3.9% higher (P = 0.015).24
In HF, there were some data that support the efficacy, safety, and tolerability of beginning β 
blockers early in patients presenting with clinical signs and symptoms of HF.25-27 But those 
studies included patients with a diagnosis of chronic HF at least 3 months prior and did 
not include de novo HF. There have been few studies to evaluate the prognostic implications 
of guideline-directed therapy according to the temporal course of HF. In this study, the 
beneficial effect of guideline directed therapy was more pronounced in de novo HF. However, 
we could not identify the pathophysiologic explanation for the difference in prognoses 
according to the time course of HF. There are possible assumptions for the explanation. 
First, because early initiation of neurohumoral pathway modulators may prevent or slow 
ventricular remodeling, guideline-directed therapy in the early course of the disease has more 
noticeable prognostic implication. Second, the beneficial effect of neurohumoral modulators 
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Table 3. Risk-adjusted performance measures-outcome link
Variables De novo heart failure Acute decompensated heart failure
HR (95% CI) P value HR (95% CI) P value
ACEI or ARB
Rehospitalization 0.57 (0.34–0.95) 0.03 1.05 (0.74–1.51) 0.77
Mortality 0.41 (0.24–0.69) < 0.001 0.58 (0.38–0.89) 0.01
Composite end point 0.52 (0.36–0.77) < 0.001 0.83 (0.63–1.10) 0.20
β-blocker
Rehospitalization 0.62 (0.41–0.95) 0.03 0.75 (0.55–1.01) 0.06
Mortality 0.67 (0.42–1.06) 0.09 0.67 (0.45–1.01) 0.06
Composite end point 0.65 (0.47–0.90) 0.01 0.71 (0.55–0.91) 0.01
MRA
Rehospitalization 0.89 (0.57–1.39) 0.61 0.86 (0.63–1.17) 0.33
Mortality 1.03 (0.63–1.67) 0.92 0.83 (0.55–1.24) 0.36
Composite end point 0.99 (0.70–1.39) 0.94 0.84 (0.65–1.08) 0.16
Multivariable Cox regression adjusted for gender, age, history of hypertension, diabetes mellitus, ischemic heart 
disease, chronic obstructive pulmonary disease, New York Heart Association functional class, systolic blood 
pressure, heart rate, creatinine, atrial fibrillation at admission and left ventricular ejection fraction.
HR = hazard ratio, CI = confidence interval, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-
receptor II blocker, MRA = mineralocorticoid receptor antagonists.
in ADCHF may simply reflect that the efficacy of therapy is modest once a patient undergoes 
decompensation while on chronic therapy.
The usefulness of aldosterone receptor antagonists in the setting of acute decompensated 
heart failure has not been determined. Current evidence from randomized aldactone 
evaluation study (RALES) supporting the use of aldosterone receptor antagonists is based on 
long-term clinical outcome data, but the acute effects of these agents are less established.28 
In contrast to data from the RALES, there was conflicting results of the prognostic 
implications of MRA.8,9 ACCF/AHA/AMA-PCPI 2011 performance measures for adults with 
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Fig. 3. 60-day event free survival according to the adherence of performance measures at discharge in ADCHF (blue line: with adherence, red line: without 
adherence). 
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor II blocker, MRA = mineralocorticoid receptor antagonists, ADCHF = acute 
decompensated chronic heart failure.
heart failure did not adapt MRA as performance measures.29 MRA was not associated with 
prognosis in both heart failure groups in this study.
Some limitations of our study merit emphasis. First, treatment options are entirely 
dependent on the attending physician in the KorAHF registry; so, selection bias may exist. 
Risk-treatment mismatch is present in the guideline-directed therapy. ADCHF is associated 
with increased comorbidity and deteriorated cardiac function; hence, patients with ADCHF 
were at increased risk of death. However, rates of treatment with guideline-directed therapy 
were low in high-risk patients. Second, the influence of background therapy and dose of each 
guideline-directed therapy were not analyzed because of the limited number of subjects. 
Third, because adherence to guidelines was defined irrespective of whether therapy was 
prescribed at discharge, the doses of therapy may not be reflected in this analysis. Fourth, HF 
duration may have influenced prognosis; however, we have no data regarding HF duration 
in patients with ADCHF. Finally, drug adherence during follow up period also may have an 
impact on the prognosis; however, this was not considered in the present study.
In conclusion, the 2 forms of HF are distinct with regard to baseline characteristics, 
comorbidity, and prognosis. The prognostic implications of adherence to guideline-directed 
therapy at discharge were more pronounced in de novo HF. We recommend that guideline-
directed therapy be started as early as possible in the course of HFrEF.
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